Skip to main content
. 2017 Jan 27;23(2):82–94. doi: 10.1002/psc.2954

Table 1.

Peptide therapeutics on the market

Trade name Peptide Company Molecular properties Related reference
Copaxone Glatiramer Teva Four amino acids (l‐glutamic acid, l‐alanine, l‐lysine and l‐tyrosine) in a defined molar ratio 105, 106
Lupron Leuprolide Abbott Synthetic nonapeptide analogue of naturally occurring gonadotropin‐releasing hormone (GnRH or LH‐RH) 107, 108
Vicoza Liraglutide Novo 97% homologous to native human GLP‐1 (7–37) by substituting arginine for lysine at position 34 and addition of a fatty acid chain 109
Zoladex Goserelin AZ Natural LHRH/GnRH decapeptide with two substitutions to inhibit rapid degradation. 110, 111
Sandostatin Octreotide Novartis Longer acting synthetic octapeptide analogue of naturally occurring somatostatin 112, 113
Forteo Teriparatide Lilly/Amylin Recombinant form of parathyroid hormone consisting of the first (N‐terminus) 34 amino acids, which is the bioactive portion of the hormone 114, 115
Byetta Exenatide Lilly/Amylin Synthetic version of exendin‐4, a hormone found in the saliva of the Gila monster 116, 117
Cubicin Daptomycin Cubist Cyclic lipopeptide, consisting of 13 amino acids, 10 of which are arranged in a cyclic fashion and three on an exocyclic tail 118, 119
Integrilin Eptifibatide Merck Cyclic heptapeptide composed with S–S bridge, two unnatural building blocks and amide 120, 121
Angiomax/angiox Bivalirudin Medicines 20‐amino acid polypeptide 122, 123
Fortical Calcitonin Upsher‐Smith 32‐amino acid polypeptide 124, 125, 126
Somatuline Lanreotide Ipsen Cyclic peptide that is a long‐acting analogue of somatostatin. 127, 128